Richmond Pharmacology | London, United Kingdom

Research site

(Unclaimed)

Location

1a Newcomen St, London, London, City of, England

Site insights

Top conditions

Top treatments

FOR-6219

Moxifloxacin

Eplontersen

RV521

UPB-101

INZ-701

Cuprior®

AST-008

ION-682884

Trientine Base

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 47 total trials

A Phase 1 Single Dose and Multiple Ascending Dose Study to Assess the Relative Bioavailability, Food Effect, Safety, Tolerability and Pharmacokinetics of SYT-510 in Healthy Participants

Part 1 aims to investigate the relative bioavailability of a new formulation and to assess potential food effects following oral administration of SY...

Enrolling

Healthy

Drug: SYT-510

Drug: Placebo

A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthenia

The goal of this clinical trial is to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Participan...

Active, not recruiting

Glanzmann Thrombasthenia

Drug: HMB-001

A Study Assessing HMB-002 in Participants With Von Willebrand Disease

This is a first-in-human (FIH), Phase 1/2, open-label, dose escalation, safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and efficac...

Enrolling

Von Willebrand Disease (VWD), Type 1

Von Willebrand Disease (VWD)

Drug: HMB-002 (Part A)

Drug: HMB-002 (Part B)

An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

The purpose of this study is to evaluate the safety and tolerability of extended dosing with eplontersen in participants with ATTR-CM.

Enrolling

Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

Drug: Eplontersen

CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

To evaluate the efficacy of eplontersen compared to placebo in participants with ATTR-CM receiving available standard of care (SoC). For more informa...

Active, not recruiting

Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)

Drug: Eplontersen

Drug: Placebo

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.

Enrolling

Transthyretin Amyloidosis (ATTR) With Cardiomyopathy

Drug: Placebo

Biological: NTLA-2001

Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants

Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy Who Compl...

Active, not recruiting

Amyloid Cardiomyopathy, Transthyretin-Related

Drug: Acoramidis (AG10)

Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients

The first-in-human Phase 1/Phase 2a study described herein will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of...

Enrolling

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Drug: ADX-038

Drug: Placebo

Trial sponsors

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms